Xellia Pharms Aps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and what generic alternatives to XELLIA PHARMS APS drugs are available?
XELLIA PHARMS APS has sixteen approved drugs.
There are seven US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.
Summary for Xellia Pharms Aps
International Patents: | 50 |
US Patents: | 7 |
Tradenames: | 10 |
Ingredients: | 10 |
NDAs: | 16 |
Drugs and US Patents for Xellia Pharms Aps
International Patents for Xellia Pharms Aps Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 59851 | ⤷ Try a Trial |
Israel | 252120 | ⤷ Try a Trial |
China | 111093625 | ⤷ Try a Trial |
Poland | 3542812 | ⤷ Try a Trial |
Brazil | 112017009405 | ⤷ Try a Trial |
South Korea | 102603756 | ⤷ Try a Trial |
Japan | 2017533218 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Xellia Pharms Aps Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0788511 | SPC/GB08/036 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
0620232 | 44/2001 | Austria | ⤷ Try a Trial | PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024 |
0788511 | 08C0028 | France | ⤷ Try a Trial | PRODUCT NAME: MICAFUNGINE; REGISTRATION NO/DATE: EU/1/08/448/001-002 20080425 |
1280520 | 300722 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 |
0620232 | SPC/GB02/002 | United Kingdom | ⤷ Try a Trial | A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016. |
0440372 | SPC/GB02/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319 |
0536515 | SPC/GB06/033 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TIGECYCLINE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.